Akebia Therapeutics (Akebia Therapeutics) EBIT per Share : $-0.24 (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics EBIT per Share?

Akebia Therapeutics's EBIT per Share for the three months ended in Dec. 2023 was $0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.24.

During the past 3 years, the average EBIT per Share Growth Rate was 55.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was 41.80% per year. During the past 10 years, the average EBIT per Share Growth Rate was 12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Akebia Therapeutics's EBIT per Share or its related term are showing as below:

AKBA' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -63.6 Med: 10.5 Max: 55.2
Current: 55.2

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Akebia Therapeutics was 55.20% per year. The lowest was -63.60% per year. And the median was 10.50% per year.

AKBA's 3-Year EBIT Growth Rate is ranked better than
93.96% of 1307 companies
in the Biotechnology industry
Industry Median: 3.4 vs AKBA: 55.20

Akebia Therapeutics's EBIT for the three months ended in Dec. 2023 was $2.0 Mil.

Akebia Therapeutics EBIT per Share Historical Data

The historical data trend for Akebia Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics EBIT per Share Chart

Akebia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-2.42

-2.73

-1.59

-0.43

-0.25

Akebia Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-0.02	-0.13	-0.05	-0.07	0.01

Akebia Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Akebia Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-45.893	/	187.465
=	-0.24

Akebia Therapeutics's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	2.032	/	189.930
=	0.01

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.24

Akebia Therapeutics (NAS:AKBA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Akebia Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Akebia Therapeutics (Akebia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (NAS:AKBA) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

AX9:Germany AX9:Germany

Address

245 First Street, Cambridge, MA, USA, 02142

Website

https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Executives

Ellen Snow	officer: SVP, CFO and Treasurer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Michel Dahan	officer: SVP, Chief Business Officer	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Nicole R. Hadas	officer: SVP, General Counsel, Sec.	20 PILGRAM DRIVE, WINCHESTER MA 01890
David A Spellman	officer: SVP, CFO and Treasurer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Steven Keith Burke	officer: SVP, Chief Medical Officer	82 WILLIS ROAD, SUDBURY MA 01776
John P. Butler	director, officer: CEO & President	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Violetta Cotreau	officer: SVP, Chief Accounting Officer	245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Ron Frieson	director	245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Dell Faulkingham	officer: CCO	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Leanne M Zumwalt	director	C/O THE ADVISORY BOARD CO WATERGATGE, 600 NEW HAMPSHIRE AVE NW, WASHINGTON DC 20037
Maxine Gowen	director
Cynthia Smith	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Myles Wolf	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Karen L Tubridy	officer: SVP, Chief Development Officer	ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142